Our findings confirmed that SFXN3 was significantly higher in AML patients (6.89 ± 7.74) than in volunteers (1.08 ± 0.43) (p < 0.01) (Fig. 2a). This evidence concerns the gene SFXN3 and acute myeloid leukemia.